iShares Nasdaq Biotechnology ETF (IBB)
With net assets of $8.05 billion, this fund seeks to track the investment results of the NASDAQ Biotechnology Index. However, IBB is currently beating the fund and is up 11.56% year-to-date (YTD).
Top holdings include some of the most respected names in biotech: Celgene, Biogen, Amgen, Gilead Sciences, and Regeneron Pharmaceuticals.
Expense ratio: 0.48%.